Loading
A phase 1/2 trial of Cemiplimab in prostate cancer and renal cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors is a phase 1/2 interventional study registered as NCT03972657 by Regeneron Pharmaceuticals, with 345 participants planned, started 2019-08-12 and due to reach its primary completion in 2027-11-15. Interventions recorded: REGN5678, Cemiplimab. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regeneron, Cemiplimab, Metastatic castration-resistant prostate cancer, Renal cell carcinoma.
Shares Regeneron, Cemiplimab, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Regeneron, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/